Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-20	$3.045	+4.28%	21,077
26-10-19	$2.920	-13.10%	76,136
26-10-16	$3.360	-0.59%	24,544
26-10-15	$3.380	+0.90%	52,659
26-10-14	$3.350	+3.40%	39,422

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.920USD

Average target price

37.50USD

Spread / Average Target

+1,184.25%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Scienture Holdings, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Scienture Holdings, Inc.

Company calendar

Market Closed - Nasdaq 04:00:00 2026-10-20 pm EDT			5-day change	1st Jan Change
3.050 ^USD	+4.45%		-21.99%	-76.08%

Aug. 13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI

Market Cap	4.8M 4.27M 3.96M 3.59M 6.74M 454M 6.85M 47.48M 18.65M 238M 17.99M 17.62M 759M	P/E 2026 *	-0.51x	P/E 2027 *	-
Enterprise Value	4.8M 4.27M 3.96M 3.59M 6.74M 454M 6.85M 47.48M 18.65M 238M 17.99M 17.62M 759M	EV / Sales 2026 *	1x	EV / Sales 2027 *	0.28x
Free-Float	77.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	SCNX	Delayed
Tradegate	4E40	Real-time
CBOE	SCNX	Real-time
Deutsche Boerse AG	4E40	Delayed

Aug. 13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI
Jul. 09	Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers	CI
Jun. 18	Scienture Holdings Expands Arbli Payor Coverage and Commercial Access	CI
Jun. 09	Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team	CI
Jun. 02	Scienture Secures US Patent Protection for Rezenopy Through 2041	MT
May. 29	Scienture - Eric Sherb resigns as CFO effective May 26, 2026	RE
May. 29	Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026	CI
May. 15	Scienture Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	Scienture secures $11.0 million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of research and development pipeline	RE
May. 07	Scienture Holdings, Inc. Secures $11 Million in Non-Dilutive Debt Financing	CI
Apr. 26	Scienture Holdings, Inc. announced that it has received $11 million in funding	CI
Mar. 30	Scienture reports year end 2025 financial results and provides business update	RE

Scienture Holdings, Inc. Stock

Stocks

SCNX

US80880X2036

Pharmaceuticals

Valuation: Scienture Holdings, Inc.

Chart: Scienture Holdings, Inc.

Latest news: Scienture Holdings, Inc.

Last Transcript: Scienture Holdings, Inc.

Analysts' recommendations: Scienture Holdings, Inc.

Press Releases: Scienture Holdings, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

25-08-14	Top Midday Decliners	MT
23-06-01	EF Hutton Assumes Trxade Health at Buy With $1.25 Price Target	MT
23-03-28	Maxim Adjusts Price Target on Trxade Health to $1.75 From $2.50, Maintains Buy Rating	MT
22-05-10	Maxim Adjusts Price Target for TRxADE Health to $4 From $7, Maintains Buy Rating	MT
22-03-29	Maxim Adjusts TRxADE HEALTH's Price Target to $7 from $11, Maintains Buy Rating	MT

Oct. 05	SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
Oct. 02	SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
Sep. 30	Scienture Holdings, Inc. Announces Reverse Stock Split	AQ
Sep. 22	SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner	AQ
Sep. 09	SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026	AQ

1 day	+4.28%
1 week	-6.02%
Current month	-53.12%
1 month	-60.03%
3 months	-70.72%
6 months	-70.83%
Current year	-76.12%

1 week	2.81	3.68
1 month	2.81	8.72
Current year	2.81	16.11
1 year	2.81	65
3 years	2.81	335.5
5 years	2.81	335.5
10 years	2.81	335.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/19/24	Narasimhan Mani	Conversion	Director	2,927,538	-
9/19/24	Shankar Hariharan	Conversion	Chief Executive Officer	3,853,296	-
7/25/24	Narasimhan Mani	Other	Director	57,977	4.1225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCIENTURE HOLDINGS, INC.	+4.28%	-6.02%	-76.06%	-	4.8M
ELI LILLY AND COMPANY	+4.04%	+10.20%	+58.91%	+119.88%	1,106B
JOHNSON & JOHNSON	+2.30%	+4.33%	+33.89%	+69.53%	612B
ABBVIE INC.	+2.70%	+4.91%	+24.03%	+96.83%	500B
ROCHE HOLDING AG	+2.58%	+8.31%	+37.43%	+63.51%	367B
MERCK & CO., INC.	+4.49%	+4.35%	+71.63%	+44.30%	354B
NOVARTIS AG	+1.85%	+5.45%	+21.38%	+49.26%	286B
ASTRAZENECA PLC	+1.76%	+4.92%	+0.48%	+20.31%	256B
AMGEN INC.	+3.23%	+5.93%	+44.17%	+56.85%	230B
GILEAD SCIENCES, INC.	+2.25%	+5.45%	+26.70%	+100.49%	190B
Average	+2.92%	+0.80%	+24.26%	+69.00%	390.02B
Weighted average by Cap.	+3.03%	+2.27%	+40.63%	+80.48%

	2026 *	2027 *
Net sales	4.79M 4.26M 3.95M 3.58M 6.73M 454M 6.84M 47.4M 18.62M 237M 17.96M 17.59M 757M	17.22M 15.32M 14.2M 12.87M 24.19M 1.63B 24.59M 170M 66.95M 854M 64.58M 63.24M 2.72B
Net income	-9.62M -8.56M -7.94M -7.19M -13.52M -912M -13.74M -95.24M -37.42M -477M -36.09M -35.34M -1.52B	135K 120K 111K 101K 190K 12.79M 193K 1.34M 525K 6.69M 506K 496K 21.35M
Net Debt	-	-